Silvia Sánchez-Ramón-rekin lankidetzan egindako argitalpenak (4)

2017

  1. Multimarker risk stratification approach at multiple sclerosis onset

    Clinical Immunology, Vol. 181, pp. 43-50

2010

  1. IFNβ-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: A longitudinal 1-year study

    Clinical Immunology, Vol. 134, Núm. 2, pp. 148-157

2009

  1. Clinical response to interferon-β-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells. Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: A 1-year longitudinal study

    Journal of Neuroimmunology, Vol. 212, Núm. 1-2, pp. 112-120

2007

  1. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis

    Journal of Neuroimmunology, Vol. 182, Núm. 1-2, pp. 204-211